- Home
- GNFT vs BDTX Comparison
GNFT vs BDTX Comparison
Compare GNFT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- BDTX
- Stock Information
- Founded
- GNFT 1999
- BDTX 2014
- Country
- GNFT France
- BDTX United States
- Employees
- GNFT N/A
- BDTX N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNFT Health Care
- BDTX Health Care
- Exchange
- GNFT Nasdaq
- BDTX Nasdaq
- Market Cap
- GNFT 186.3M
- BDTX 181.4M
- IPO Year
- GNFT 2019
- BDTX 2020
- Fundamental
- Price
- GNFT $3.94
- BDTX $2.94
- Analyst Decision
- GNFT Strong Buy
- BDTX Strong Buy
- Analyst Count
- GNFT 2
- BDTX 6
- Target Price
- GNFT $11.00
- BDTX $12.50
- AVG Volume (30 Days)
- GNFT 3.9K
- BDTX 802.5K
- Earning Date
- GNFT 09-22-2025
- BDTX 11-04-2025
- Dividend Yield
- GNFT N/A
- BDTX N/A
- EPS Growth
- GNFT N/A
- BDTX N/A
- EPS
- GNFT 0.03
- BDTX 0.25
- Revenue
- GNFT $73,187,701.00
- BDTX $70,000,000.00
- Revenue This Year
- GNFT $5.15
- BDTX N/A
- Revenue Next Year
- GNFT N/A
- BDTX N/A
- P/E Ratio
- GNFT $129.03
- BDTX $11.74
- Revenue Growth
- GNFT 105.01
- BDTX N/A
- 52 Week Low
- GNFT $2.55
- BDTX $1.20
- 52 Week High
- GNFT $6.42
- BDTX $6.33
- Technical
- Relative Strength Index (RSI)
- GNFT 47.31
- BDTX 57.58
- Support Level
- GNFT $3.84
- BDTX $2.56
- Resistance Level
- GNFT $4.40
- BDTX $2.95
- Average True Range (ATR)
- GNFT 0.12
- BDTX 0.16
- MACD
- GNFT -0.04
- BDTX 0.02
- Stochastic Oscillator
- GNFT 12.48
- BDTX 79.00
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.